Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
53
ABBV Quote, Financials, Valuation and Earnings
Last price:
$219.59
Seasonality move
:
1.09%
Day range:
$225.30 - $229.29
52-week range:
$164.39 - $244.81
Dividend yield:
2.95%
P/E ratio:
95.44x
P/S ratio:
6.53x
P/B ratio:
247.77x
Volume:
7.6M
Avg. volume:
7.2M
1-year change:
6.28%
Market cap:
$398.5B
Revenue:
$61.2B
EPS (TTM):
$2.36
Analysts' Opinion
-
Consensus RatingAbbVie, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 9 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $248.86, AbbVie, Inc. has an estimated upside of 10.42% from its current price of $227.68.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $184.00 representing 18.36% downside risk from its current price of $227.68.
Fair Value
-
According to the consensus of 22 analysts, AbbVie, Inc. has 10.42% upside to fair value with a price target of $248.86 per share.
ABBV vs. S&P 500
-
Over the past 5 trading days, AbbVie, Inc. has underperformed the S&P 500 by -3.52% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
AbbVie, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AbbVie, Inc. has grown year-over-year revenues for 8 quarters straight. In the most recent quarter AbbVie, Inc. reported revenues of $16.6B.
Earnings Growth
-
AbbVie, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter AbbVie, Inc. reported earnings per share of $1.02.
Enterprise value:
461.5B
EV / Invested capital:
7.10x
Price / LTM sales:
6.53x
EV / EBIT:
23.00x
EV / Revenue:
7.55x
PEG ratio (5yr expected):
--
EV / Free cash flow:
25.90x
Price / Operating cash flow:
22.42x
Enterprise value / EBITDA:
16.32x
Gross Profit (TTM):
$42.9B
Return On Assets:
3.1%
Net Income Margin (TTM):
6.86%
Return On Equity:
144.3%
Return On Invested Capital:
6.1%
Operating Margin:
34.23%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $54.3B | $56.3B | $61.2B | $15.1B | $16.6B | |
| Gross Profit | $38.2B | $39.5B | $42.9B | $10.7B | $12.1B | |
| Operating Income | $20.1B | $16.6B | $20.1B | $4.7B | $5.7B | |
| EBITDA | $28.8B | $25B | $28.3B | $6.8B | $7.7B | |
| Diluted EPS | $2.72 | $2.39 | $2.36 | -$0.02 | $1.02 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $27.9B | $28.5B | $33B | $25.6B | $29.1B | |
| Total Assets | $146.5B | $138.8B | $134.7B | $135.2B | $134B | |
| Current Liabilities | $35.2B | $29.5B | $37.8B | $38.7B | $43.3B | |
| Total Liabilities | $131.1B | $121.5B | $124.3B | $131.8B | $137.2B | |
| Total Equity | $15.4B | $17.3B | $10.4B | $3.4B | -$3.2B | |
| Total Debt | $77.4B | $64B | $60.1B | $67.8B | $65.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $22.8B | $18.8B | $19B | $7B | $5.2B | |
| Cash From Investing | -$2B | -$20.8B | -$6.6B | -$1.9B | -$1.5B | |
| Cash From Financing | -$17.2B | -$5.2B | -$12.7B | -$6.9B | -$4.2B | |
| Free Cash Flow | $22B | $17.8B | $17.8B | $6.8B | $4.9B | |
ABBV
Sector
Market Cap
$398.5B
$25.3M
Price % of 52-Week High
92.06%
48.74%
Dividend Yield
2.95%
0%
Shareholder Yield
3.21%
-1.64%
1-Year Price Total Return
6.28%
-19.12%
Beta (5-Year)
0.341
0.492
Dividend yield:
2.95%
Annualized payout:
$6.56
Payout ratio:
169.94%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$231.11
200-day SMA
Buy
Level
$214.21
Bollinger Bands (100)
Buy
Level
220.43 - 231.17
Chaikin Money Flow
Buy
Level
1.1B
20-day SMA
Sell
Level
$229.06
Relative Strength Index (RSI14)
Sell
Level
49.86
ADX Line
Sell
Level
8.46
Williams %R
Neutral
Level
-73.4439
50-day SMA
Buy
Level
$224.92
MACD (12, 26)
Buy
Level
1.39
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
1.5B
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.449)
Sell
CA Score
(Annual)
Level (-1.8811)
Buy
Beneish M-Score
(Annual)
Level (-2.8675)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.8209)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Stock Forecast FAQ
In the current month, ABBV has received 13 Buy ratings 9 Hold ratings, and 0 Sell ratings. The ABBV average analyst price target in the past 3 months is $248.86.
-
Where Will AbbVie, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that AbbVie, Inc. share price will rise to $248.86 per share over the next 12 months.
-
What Do Analysts Say About AbbVie, Inc.?
Analysts are divided on their view about AbbVie, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AbbVie, Inc. is a Sell and believe this share price will drop from its current level to $184.00.
-
What Is AbbVie, Inc.'s Price Target?
The price target for AbbVie, Inc. over the next 1-year time period is forecast to be $248.86 according to 22 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 9 analysts rate the stock a Hold.
-
Is ABBV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AbbVie, Inc. is a Buy. 13 of 22 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ABBV?
You can purchase shares of AbbVie, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AbbVie, Inc. shares.
-
What Is The AbbVie, Inc. Share Price Today?
AbbVie, Inc. was last trading at $219.59 per share. This represents the most recent stock quote for AbbVie, Inc.. Yesterday, AbbVie, Inc. closed at $227.68 per share.
-
How To Buy AbbVie, Inc. Stock Online?
In order to purchase AbbVie, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ABBV Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ABBV
Sector
P/E ratio
95.44x
21.47x
PEG ratio
--
-0.01x
P/B ratio
247.77x
1.74x
Price / LTM sales
6.53x
1.45x
Growth Metrics
ABBV
Sector
Revenue growth
10.04%
3.36%
Earnings growth
5724.31%
11.93%
Revenue (5-year growth)
5.95%
6.25%
Earnings forecast
$2.65
-$0.20
Profitability
ABBV
Sector
Profitability FY 2025
$42.9B
$2.2M
Return on invested capital
6.1%
-33.31%
Return on assets
3.1%
-29.82%
Return on equity
144.3%
-40.01%
Earnings Date
Last Earnings Date
Feb
4
Next Earnings Date
May
1
Estimated Next Earnings Date
May
6
Balance Sheet
ABBV
Sector
Total cash
$5.3B
$24.9M
Short term investments
$31M
$23.2M
Total assets
$134B
$69.8M
Long term debt
$65.7B
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
